Voriconazole: a new triazole antifungal agent

Clicks: 279
ID: 113557
2003
Voriconazole is a second-generation azole antifungal agent that shows excellent in vitro activity against a wide variety of yeasts and molds. It can be given by either the intravenous or the oral route; the oral formulation has excellent bioavailability. The side effect profile of voriconazole is un …
Reference Key
lb2003clinicalvoriconazole: Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Johnson LB;Kauffman CA;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2003
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/12594645
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine microbial sensitivity tests liver / drug effects antifungal agents / therapeutic use pmid:12594645 doi:10.1086/367933 leonard b johnson carol a kauffman antifungal agents / adverse effects antifungal agents / pharmacology* aspergillosis / drug therapy aspergillus / drug effects candida / drug effects* dermatitis / etiology drug interactions exanthema / etiology pyrimidines / adverse effects pyrimidines / pharmacology* pyrimidines / therapeutic use triazoles / adverse effects triazoles / pharmacology* triazoles / therapeutic use voriconazole

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.